Premium
Waiting for Godot: Anticipating answers on embolic protection unlikely to arrive
Author(s) -
Anouti Khalil,
Gray William A.
Publication year - 2018
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27879
Subject(s) - medicine , asymptomatic , stroke (engine) , embolic stroke , clinical endpoint , surrogate endpoint , intensive care medicine , emergency medicine , surgery , ischemic stroke , randomized controlled trial , mechanical engineering , ischemia , engineering
Key Points For symptomatic and asymptomatic patient with high or intermediate risk of CEA complications, CAS with the use of EPDs has a very low rate of in‐hospital stroke and death There is no statistically significant difference in ipsilateral stroke/TIA and any stroke/TIA between the different device platforms Further efforts to assess differences between EPD devices would likely need to involve a surrogate endpoint due to the very low rates of clinical events
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom